GIST: Clinical Trials

5 trials for GIST, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed. 5 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 25Completed 5

Follow GIST: new trials by email Literature Review of GIST trials Research Report on GIST

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Temozolomide (TMZ) In Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST)
Temozolomide - Gastrointestinal Stromal Tumors, Sdh
Phase 2CompletedAdam Burgoyne, MD, PhD232018-09-122026-07-28
Phase II Trial of Vandetanib in Children and Adults With Wild-Type Gastrointestinal Stromal Tumors
Vandetanib - GIST
Phase 2CompletedNational Cancer Institute (NCI)92013-12-142020-03-30
A Phase 2 Trial of Ponatinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor
Ponatinib - GIST
Phase 2CompletedAriad Pharmaceuticals452013-06-052018-05-18
Efficacy of Pazopanib in Gastrointestinal Stromal Tumors (GIST)
Pazopanib, Best supportive care - GIST
Phase 2CompletedCentre Leon Berard812011-03-012016-02-25
An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BIIB021 in Subjects With Gastrointestinal Stromal Tumors (GIST)
BIIB021 - GIST
Phase 2CompletedBiogen202008-02-012015-10-02

Narrower conditions

Gastrointestinal Stromal Tumors (2)  ·  Gastrointestinal Neoplasms (1)  ·  Hematoma, Subdural (1)  ·  Neoplasms (1)

Broader conditions

Digestive System Diseases (2)  ·  Digestive System Neoplasms (2)  ·  Gastrointestinal Diseases (2)  ·  Neoplasms by Histologic Type (2)  ·  Neoplasms, Connective Tissue (2)  ·  Neoplasms, Connective and Soft Tissue (2)  ·  Brain Diseases (1)  ·  Cardiovascular Diseases (1)  ·  Central Nervous System Diseases (1)  ·  Cerebrovascular Disorders (1)  ·  Craniocerebral Trauma (1)  ·  Gastrointestinal Neoplasms (1)  ·  Hematoma (1)  ·  Hemorrhage (1)  ·  Intracranial Hemorrhage, Traumatic (1)

Interventions

6-chloro-9-(4-methoxy-3,5-dimethylpyridin-2-ylmethyl)-9H-purin-2-ylamine (1)  ·  Temozolomide (1)  ·  pazopanib (1)  ·  ponatinib (1)  ·  vandetanib (1)

Sponsors

Adam Burgoyne, MD, PhD (1)  ·  Ariad Pharmaceuticals (1)  ·  Biogen (1)  ·  Centre Leon Berard (1)  ·  National Cancer Institute (NCI) (1)

Countries

United States (4)  ·  France (1)

Top investigators

Adam Burgoyne, MD, PhD (1)  ·  Brigitte C Widemann, M.D. (1)  ·  Jason Sicklick, MD (1)

Results publications

PMID 27068858